Endemic equilibrium cometh

Virus is close to reaching “endemic equilibrium” Update on Balira Link to original Wefeafwa video https://www.youtube.com/watch?v=mV7a9MMFbRg&t=15s If you would like to support our community health outreach in Uganda (100% of donations go directly to Wefwafwa) patreon:https://www.patreon.com/awmedicalvideos Donate: SENDWAVE/ WorldRemit /Western Union/Money Gram Mobile money number:+256785698803 Country: Uganda Registered name : Wefwafwa Andrew State: Eastern uganda Zip code:0000 Wallet Service provider:MTN City: Mbale city please email me when you send or to talk with me directly, [email protected] London School of Hygiene and Tropical Medicine https://www.telegraph.co.uk/news/2021/10/24/coronavirus-cases-slump-winter-say-scientists/ Imminent drops in infections Cases could fall to around 5,000 a day before Christmas Prof John Edmunds, Centre for the Mathematical Modelling of Infectious Diseases, LSHTM Member of SAGE Our model was projecting that cases would start to decline some time in the autumn. However, the model also suggests that cases may start to climb again in the spring, due to a combination of waning immunity and increased contacts Cases currently being driven by high case rates in children Virus is close to reaching “endemic equilibrium” Recent oscillations in case rates will soon level Rishi Sunak at the moment the data does not suggest that we should be immediately moving to 'Plan B Maggie Throup, UK vaccines minister 'Plan A' is working, situation where we need to be United States Pfizer for children, 5 to 11, FDA votes for EMU tomorrow From first half of November 2 shots, 3 weeks gap One third of adult dose 25,000 centres signed up for roll out 28 million children in demographic https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-initial-data-us-fda-pivotal https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results https://www.businesswire.com/news/home/20210920005452/en/ https://www.fda.gov/media/153447/download Results are the first from a pivotal trial of any COVID-19 vaccine in children under 12 years of age In participants 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responses Phase 2/3 study United States, Finland, Poland, Spain Children 6 months to 11 years of age N = 2,268 5 to 11 years of age Received a 10 µg dose level in a two-dose regimen Strong SARS-CoV-2–neutralizing antibody response, one month after the second dose Continue to accumulate the safety and efficacy data Topline readouts for the other two age cohorts from the trial, soon Children 2-5 years of age Children 6 months to 2 years of age About the Phase 1/2/3 Trial in Children N = 4,500 children ages 6 months to 11 years More than 90 clinical trial sites Children under 5 received a 3 µg dose Trial enrolled children with or without prior evidence of SARS-CoV-2 infection ONS https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights Reduction in self-reported long COVID after vaccination https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19vaccinationandselfreportedlongcovidintheuk/25october2021 Identified themselves as experiencing persistent symptoms 12 weeks after first infection A first vaccine dose was associated with an initial 13% decrease in self-reported long COVID, and a further 9% sustained decrease after receiving the second vaccination No evidence of differences in self-reported between Oxford/AstraZeneca vaccine, compared to Pfizer/BioNTech or Moderna vaccines UK, 30 June to 17 October 2021 Practice falls below thinking https://www.ons.gov.uk/peoplepopulationandcommunity/h Learn more about your ad choices. Visit megaphone.fm/adchoices